<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460213</url>
  </required_header>
  <id_info>
    <org_study_id>KIT-061003-1</org_study_id>
    <secondary_id>ISRCTN1150</secondary_id>
    <nct_id>NCT00460213</nct_id>
  </id_info>
  <brief_title>Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research（VOYAGER）Study</brief_title>
  <official_title>Study on Optimal Anti-hypertensive Therapy With Valsartan by Using Home Blood Pressure Measurement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kitakyushu-Tsuyazaki Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kitakyushu-Tsuyazaki Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare improvement percentage of urinary albumin excretion&#xD;
      between valsartan 80 mg- and valsartan 160 mg-based therapy in patient with morning&#xD;
      hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The cardiovascular diseases such as stroke and myocardial infarction consist 50% of the cause&#xD;
      of death in Japanese population. Numerous mega trials have shown that strict&#xD;
      anti-hypertensive therapy could reduce cardiovascular morbidity and mortality in hypertensive&#xD;
      patients.&#xD;
&#xD;
      It is reported, however, over 50% hypertensive patients have not been controlled below&#xD;
      therapeutic target blood pressure that the JSH2004 guideline recommends.&#xD;
&#xD;
      Recently use of Angiotensin II receptor blockers (ARBs) is increasing progressively for their&#xD;
      pharmacological action on organ protection as well as potent reduction in blood pressure.&#xD;
      However, usual dosage of ARB in Japan is almost half of that in the mega trials executed in&#xD;
      Europe and America. Lower dosage compared to western countries might be a reason why&#xD;
      cardiovascular events are not fully reduced in Japan.&#xD;
&#xD;
      Valsartan optimal therapy against elevated home blood pressure research (VOYAGER) study will&#xD;
      be a multi-center, open-label, randomized, active-controlled study to evaluate the following;&#xD;
      improvement percentage of urinary albumin exception, home blood pressure, hospital blood&#xD;
      pressure, incidence of stroke, cardiovascular disease, and microangiopathy with valsartan 80&#xD;
      mg- or valsartan 160 mg based therapy in patients with elevated morning home blood pressure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement percentage of urinary albumin excretion</measure>
    <time_frame>3, 6, 9, and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>home blood pressure; hospital blood pressure; stroke; cardiovascular disease; microangiopathy</measure>
    <time_frame>every month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 80mg daily</intervention_name>
    <arm_group_label>Valsartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 160mg daily</intervention_name>
    <arm_group_label>Valsartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients aged over 20 years and less than 80 years, regardless of sex.&#xD;
&#xD;
          -  Patients with stable seated morning home blood pressure of over 135 mmHg and/or&#xD;
             diastolic blood pressure of over 85 mmHg within 1 to 2 weeks.&#xD;
&#xD;
          -  Patients who are on therapy with conventional dosage of ARB.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are difficult to measure home blood pressure.&#xD;
&#xD;
          -  Patients with secondary hypertension or malignant hypertension.&#xD;
&#xD;
          -  Patients with seated systolic blood pressure of over 200 mmHg.&#xD;
&#xD;
          -  Patients with seated diastolic blood pressure of over 120 mmHg.&#xD;
&#xD;
          -  Patients with a history of cerebrovascular disorder or myocardial infarction or heart&#xD;
             failure within 6 months prior to enrolment in the study.&#xD;
&#xD;
          -  Patients with atrial fibrillation, atrial flutter, or serious arrhythmia.&#xD;
&#xD;
          -  Patients with renal dysfunction with serum creatinine level of over 2 mg/dL.&#xD;
&#xD;
          -  Patients with serious liver dysfunction.&#xD;
&#xD;
          -  Patient with HbA1C of over 8 percent.&#xD;
&#xD;
          -  Patient with positive albuminuria by dip and read stick test.&#xD;
&#xD;
          -  Patient treated with any angiotensin converting enzyme inhibitor&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Patients with a history of hypersensitivity to valsartan.&#xD;
&#xD;
          -  Other patients who are judged to be inappropriate for the study by the investigator or&#xD;
             sub-investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koshiro Fukiyama, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Japan Seamen's Relief Association Moji Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Koshiro Fukiyama</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>808-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>March 28, 2007</study_first_submitted>
  <study_first_submitted_qc>April 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2007</study_first_posted>
  <last_update_submitted>December 5, 2013</last_update_submitted>
  <last_update_submitted_qc>December 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kitakyushu-Tsuyazaki Hospital</investigator_affiliation>
    <investigator_full_name>Koshiro Fukiyama</investigator_full_name>
    <investigator_title>Honorary Director</investigator_title>
  </responsible_party>
  <keyword>home blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

